TransCode Therapeutics Q4 2024 Earnings Deep Losses Reflect PreRevenue Stage BlackLine Q1 2026 Earnings EPS Surges 21 Above Estimates Stock Edges Lower BMY Q1 2026 Earnings EPS Beat on Cost Discipline and Operational Execution Immunome Inc Q1 2026 Earnings NarrowerThanExpected Loss Amid No Revenue Stock Slips Goldman Sachs BDC Inc GSBD Q1 2026 Earnings Earnings Miss Estimates as Net Investment Income Underwhelms AWR Q1 2026 Earnings EPS Misses Estimates Slightly as Stock Edges Higher